ワクチンアジュバント市場- 世界の産業規模、シェア、動向、機会、および予測、2018年～2028年、製品タイプ別、用途別、地域別、競合

ワクチンアジュバントの世界市場は、2022年に7億2,000万米ドルと評価され、2028年までのCAGRは6.56%で、予測期間中に力強い成長が予測されています。

ワクチンアジュバントの世界市場は、より広範なヘルスケア産業の重要な構成要素であり、ワクチンの有効性を高め、世界の予防接種の取り組みを強化する上で極めて重要な役割を果たしています。ワクチンアジュバントは、より強力で長持ちする免疫反応を刺激するためにワクチンに添加される物質であり、最終的には感染症に対する予防効果を高めることにつながります。この市場は、ウイルス感染症、細菌性疾患、新興パンデミックなど、さまざまな疾病と闘うためのワクチン需要の増加を背景に、近年大きな成長を遂げています。

世界のワクチンアジュバント市場の拡大には、いくつかの要因が寄与しています。何よりもまず、現在進行中の情勢が、世界の公衆衛生におけるワクチンとワクチンアジュバントの重要性を浮き彫りにしました。世界各国の政府、ヘルスケア機関、製薬会社は、ワクチンの開発・配布に向けた取り組みを強化しており、免疫反応を強化し、より広範なワクチン接種を可能にするアジュバントの需要が急増しています。

さらに、バイオテクノロジーと免疫学の進歩により、安全性と有効性のプロファイルが改善された新規アジュバントの市場開拓が進み、市場が活性化しています。こうした技術革新により、従来のワクチンにおけるアジュバントの用途が拡大しただけでなく、がんやアレルギーなどの疾患に対する治療用ワクチンへの使用という新たな可能性も切り開かれています。

世界のワクチンアジュバント市場は、感染症と闘うワクチンの緊急ニーズとアジュバント技術の絶え間ない革新に牽引され、力強い成長を遂げています。世界が感染症の脅威と闘い続ける中、免疫反応を強化しワクチンの有効性を向上させるワクチンアジュバントの役割はさらに顕著になり、世界の公衆衛生活動の重要な構成要素としてこの市場の地位は確固たるものになると考えられます。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 ワクチンアジュバントの世界市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別（アジュバントエマルジョン、病原体成分、サポニンベースアジュバント、粒子状アジュバント、その他アジュバント）
  • タイプ別（ヒトワクチンアジュバント、動物ワクチンアジュバント）
  • 用途別（研究用途、商業用途）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 製品別
  • タイプ別
  • 用途別
  • 地域別

第5章 アジア太平洋地域のワクチンアジュバント市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • タイプ別
  • 用途別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のワクチンアジュバント市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • タイプ別
  • 用途別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のワクチンアジュバント市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • タイプ別
  • 用途別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のワクチンアジュバント市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • タイプ別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのワクチンアジュバント市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • タイプ別
  • 用途別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 ワクチンアジュバントの世界市場SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Dynavax Technologies
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Current Capacity Analysis
  • Financials（In case of listed）
  • Recent Developments
  • SWOT Analysis
• Croda International Plc
• Gsk Plc
• Novavax
• Spi Pharma（A Subsidiary of Associated British Foods Plc）
• Agenus Inc.
• Phibro Animal Health Corporation
• Aurorium（Formerly Vertellus）
• Merck Kgaa
• Vaxine Pty Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Vaccine Adjuvants Market has valued at USD 0.72 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 6.56% through 2028. The Global Vaccine Adjuvants Market is a critical component of the broader healthcare industry, playing a pivotal role in enhancing the efficacy of vaccines and bolstering global immunization efforts. Vaccine adjuvants are substances added to vaccines to stimulate a stronger and longer-lasting immune response, ultimately leading to improved protection against infectious diseases. This market has witnessed significant growth in recent years, driven by the increasing demand for vaccines to combat a wide range of diseases, including viral infections, bacterial illnesses, and emerging pandemics.

Several factors have contributed to the expansion of the Global Vaccine Adjuvants Market. First and foremost, the ongoing COVID-19 pandemic has highlighted the importance of vaccines and vaccine adjuvants in the global public health landscape. Governments, healthcare organizations, and pharmaceutical companies worldwide have ramped up their efforts to develop and distribute vaccines, creating a surge in demand for adjuvants that can enhance the immune response and enable broader vaccine coverage.

Furthermore, the market has been boosted by advancements in biotechnology and immunology, leading to the development of novel adjuvants with improved safety and efficacy profiles. These innovations have not only expanded the applications of adjuvants in traditional vaccines but also opened up new possibilities for their use in therapeutic vaccines against conditions such as cancer and allergies.

The Global Vaccine Adjuvants Market is experiencing robust growth, driven by the urgent need for vaccines to combat infectious diseases and the continuous innovation in adjuvant technologies. As the world continues to grapple with infectious threats, the role of vaccine adjuvants in enhancing immune responses and improving vaccine efficacy is likely to become even more prominent, solidifying this market's position as a crucial component of global public health efforts.

Key Market Drivers

Rising Infectious Disease Threats

The Global Vaccine Adjuvants Market is experiencing a notable upswing, and one of the primary driving forces behind this growth is the persistent and escalating threat posed by infectious diseases. In recent years, the world has witnessed a series of infectious disease outbreaks and pandemics that have underscored the critical importance of vaccination and vaccine adjuvants in safeguarding public health. These threats have led to a surge in demand for adjuvants, which play a pivotal role in enhancing the efficacy of vaccines and ensuring rapid and robust immune responses.

The ongoing emergence of infectious diseases has created an urgent need for effective vaccines, and adjuvants have become indispensable tools in vaccine development. Diseases like the H1N1 influenza, Zika virus, and, most notably, the COVID-19 pandemic have ignited global efforts to develop vaccines at an unprecedented pace. Vaccine adjuvants have been instrumental in expediting this process by improving the immune system's response to these vaccines, thereby increasing their effectiveness.

Moreover, the COVID-19 pandemic has brought vaccine adjuvants into the spotlight, particularly with the development of mRNA vaccines from companies like Pfizer-BioNTech and Moderna. Lipid nanoparticles used as adjuvants in these vaccines have not only accelerated production but also significantly enhanced immunogenicity, leading to record-breaking vaccination campaigns.

The fear of recurring infectious disease threats and the potential emergence of new ones have prompted governments, healthcare organizations, and pharmaceutical companies to invest heavily in the development and production of vaccines and adjuvants. This heightened focus on vaccine research and innovation has propelled the Global Vaccine Adjuvants Market into a phase of rapid expansion, as stakeholders recognize that adjuvants are indispensable in the fight against infectious diseases.

Advancements in Immunology

Advancements in immunology have emerged as a significant driver behind the burgeoning growth of the Global Vaccine Adjuvants Market. These breakthroughs in our understanding of the immune system and its intricate responses to pathogens have propelled the development of novel and highly effective vaccine adjuvants, transforming them from mere additives to precision tools that can tailor immune responses. In recent years, immunology research has unraveled the complexities of the immune system, shedding light on how it recognizes and responds to various antigens. This deeper insight has allowed scientists and researchers to design adjuvants that can specifically target and enhance the desired immune response. For example, adjuvants can now be fine-tuned to elicit robust antibody production, long-lasting memory responses, or even targeted cellular immunity, depending on the requirements of the vaccine and the targeted pathogen.

Advancements in immunology have also facilitated the development of adjuvants that can enhance the efficacy of subunit vaccines. Subunit vaccines contain only specific components of a pathogen, making them safer but often less immunogenic. By understanding the immune system's nuances, adjuvants can be designed to augment the immune response to subunit vaccines, making them more potent and protective.

Furthermore, the identification of new immunological pathways and molecules has paved the way for innovative adjuvant formulations. Toll-like receptors (TLRs), for instance, have been recognized as key players in the immune system's response to infections. Adjuvants designed to activate TLRs can mimic the natural infection process, resulting in heightened immune responses. Other advancements include the utilization of nanoparticles, such as liposomes or virus-like particles, to encapsulate antigens and adjuvants, enhancing their delivery and immune-stimulating properties.

The synergy between immunological research and vaccine adjuvant development has expanded the possibilities of vaccination, offering solutions to previously challenging vaccine targets, such as complex pathogens like HIV or cancer antigens. This convergence of science has not only accelerated the development of new vaccines but also revitalized existing ones, as adjuvants can improve their effectiveness.

Investment in Research and Development

Investment in research and development (R&D) has emerged as a pivotal driver in propelling the remarkable growth of the Global Vaccine Adjuvants Market. The pharmaceutical and biotechnology industries, along with government agencies and academic institutions, have recognized the strategic importance of vaccine adjuvants in enhancing vaccine efficacy and broadening immunization programs. Consequently, substantial investments are being directed towards the research and development of these essential components.

Pharmaceutical companies are allocating significant resources to advance their adjuvant portfolios, aiming to refine existing adjuvants and discover novel ones. This commitment to R&D is driven by the pursuit of safer, more effective, and more targeted adjuvants that can bolster the immune response while minimizing side effects. Additionally, the success stories of adjuvants in recent vaccine developments, such as lipid nanoparticles in mRNA vaccines, have reinforced the importance of continued innovation and investment in this field.

Government agencies have also played a vital role in fueling R&D efforts related to vaccine adjuvants. Recognizing the critical role of vaccines in public health, governments are providing funding, grants, and incentives to encourage research in adjuvant technologies. These financial injections enable researchers to explore novel adjuvant candidates, conduct clinical trials, and accelerate the development process, ultimately contributing to the growth of the vaccine adjuvants market.

Academic institutions, often at the forefront of immunological research, are partnering with industry players and receiving grants to investigate new adjuvant formulations and mechanisms of action. This collaboration between academia and the private sector fosters innovation and knowledge sharing, leading to breakthrough discoveries in adjuvant science. Furthermore, the demand for adjuvants has been amplified by the urgent need for vaccines during global health crises, such as the COVID-19 pandemic. The swift development and deployment of vaccines against SARS-CoV-2 have highlighted the critical role of adjuvants in expediting vaccine production and enhancing immunogenicity. This heightened visibility has, in turn, attracted more funding and investment into adjuvant R&D..

Key Market Challenges

Regulatory Hurdles

One of the most formidable challenges for vaccine adjuvants is the arduous journey through the regulatory approval process. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require extensive preclinical and clinical data to demonstrate the safety and efficacy of new adjuvants. These rigorous requirements can significantly lengthen the timeline from development to market approval, delaying adjuvant availability and increasing development costs.

Regulatory requirements for vaccine adjuvants vary from one country or region to another. This lack of harmonization can create a complex and fragmented landscape for manufacturers seeking global approval. Adhering to multiple sets of regulations necessitates additional resources and can discourage investment in adjuvant research and development. Regulatory agencies often provide limited guidance or specific pathways for the approval of adjuvants. Manufacturers are left to navigate the regulatory process with minimal clear direction, which can result in uncertainty and potential missteps during development and submission. Clarity and consistent guidelines would be instrumental in streamlining the approval process.

Once a vaccine adjuvant is approved and in use, ongoing post-market surveillance is necessary to monitor safety and effectiveness. However, establishing robust surveillance systems and ensuring compliance with reporting requirements can be a regulatory challenge. Failure to do so can result in regulatory actions and a loss of market trust.

High Development Costs

The initial phase of developing vaccine adjuvants involves in-depth research to identify and characterize suitable adjuvant candidates. This process demands significant financial investment in laboratories, skilled researchers, and cutting-edge technologies. The costs incurred during this research phase are substantial and serve as the foundation for subsequent development stages.

Before vaccine adjuvants can progress to clinical trials, they must undergo rigorous preclinical testing to evaluate their safety and effectiveness in animal models. These studies are not only time-consuming but also expensive. Companies must cover the expenses associated with animal care, specialized facilities, and the acquisition of preclinical data. Clinical trials are the cornerstone of vaccine adjuvant development, representing a considerable portion of development costs. These trials involve recruiting human subjects, conducting extensive testing, monitoring for adverse events, and generating the necessary data to support regulatory submissions. The costs associated with designing, implementing, and analyzing these trials can be exorbitant.

Meeting the regulatory requirements imposed by agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is essential but costly. Vaccine adjuvant manufacturers must adhere to strict guidelines, conduct additional studies if requested, and invest in quality control measures to meet regulatory standards. Navigating the regulatory landscape further drives up development costs.

Key Market Trends

Expanding Consumer Markets

The Global Vaccine Adjuvants Market is experiencing a significant boost, thanks to the expansion of consumer markets across the globe. As public awareness about the importance of vaccines continues to grow, the demand for effective immunization has surged, propelling the need for vaccine adjuvants. Several factors contribute to the expansion of consumer markets and their positive impact on the vaccine adjuvants market. Rising global populations, particularly in emerging economies, are driving an increased demand for vaccines. As more people seek protection against infectious diseases, vaccine manufacturers are ramping up their production. Vaccine adjuvants play a pivotal role in enhancing the efficacy of vaccines, making them more attractive to a broader consumer base.

Furthermore, the prevalence of infectious diseases remains a global concern. Outbreaks and pandemics like the COVID-19 crisis have highlighted the critical need for vaccines to prevent and control the spread of diseases. This heightened awareness of infectious disease threats has motivated individuals and governments to invest in vaccination programs, further fueling the demand for adjuvanted vaccines.

Expanding consumer markets also encompasses a growing awareness of vaccination's role in safeguarding public health. As healthcare education becomes more accessible, people are becoming better informed about the benefits of vaccination, not only for individual protection but also for community immunity. This increased understanding has led to greater vaccine acceptance and a willingness to opt for vaccines enhanced with adjuvants for better protection.

Moreover, the aging population in many parts of the world has contributed to the expanding consumer base for vaccines. Elderly individuals are more susceptible to certain diseases, making vaccination a vital component of their healthcare. Adjuvanted vaccines, which can provide stronger and longer-lasting immunity, are particularly appealing in this demographic.

Focus on Pandemic Preparedness

The Global Vaccine Adjuvants Market is witnessing a substantial boost due to an intensified focus on pandemic preparedness. Recent global health crises, most notably the COVID-19 pandemic, have underscored the critical importance of rapidly developing effective vaccines to combat emerging infectious diseases. In this context, vaccine adjuvants have emerged as vital tools in pandemic preparedness, driving their demand and growth in the market.

The COVID-19 pandemic served as a wake-up call to governments, healthcare organizations, and pharmaceutical companies worldwide. The urgent need for vaccines to curb the spread of the virus highlighted the significance of expediting vaccine development and distribution. Vaccine adjuvants played a pivotal role in this endeavor, as they enhance the immune response to vaccines, resulting in faster and more robust protection against infectious agents.

Pharmaceutical companies and researchers swiftly recognized the potential of adjuvants in expediting vaccine production and improving vaccine efficacy. Adjuvants like lipid nanoparticles used in mRNA vaccines from Pfizer-BioNTech and Moderna have been key enablers in the rapid development and deployment of COVID-19 vaccines. This success story has ignited heightened interest and investment in adjuvant research and development, with a particular focus on innovations that can be readily applied to future pandemics.

Governments and international organizations are also actively investing in pandemic preparedness, including the development and stockpiling of adjuvanted vaccines. These efforts aim to ensure a swift response to future outbreaks, with a ready supply of effective vaccines that can be deployed globally. Adjuvanted vaccines, which can provide better immune responses even with smaller amounts of antigen, are a crucial component of this strategy. Additionally, the pandemic experience has reinforced the importance of collaboration between governments, private industry, and research institutions. Public-private partnerships and global cooperation have accelerated vaccine and adjuvant development, demonstrating the power of collective efforts in pandemic response.

Segmental Insights

Type Insights

Based on the Type, the Human Vaccine Adjuvants emerged as the dominant segment in the global market for Global Vaccine Adjuvants Market in 2022. Human vaccines are a top priority for global healthcare systems and governments due to their direct impact on public health. Preventing and controlling infectious diseases in humans is paramount, and vaccine adjuvants play a crucial role in enhancing the efficacy of these vaccines. The human vaccine market encompasses a vast and diverse range of vaccines targeting various infectious diseases. From childhood immunizations to adult vaccines and those for emerging threats like COVID-19, there is a continuous demand for adjuvanted human vaccines across all age groups..

Application Insights

Based on the Application, the Commercial Applications segment emerged as the dominant player in the global market for Global Vaccine Adjuvants Market in 2022. Commercial applications in the context of human vaccines have a profound impact on public health. Vaccination programs targeting infectious diseases like influenza, hepatitis, and human papillomavirus (HPV) are essential components of global efforts to prevent illness and save lives. The demand for adjuvants in these programs is substantial due to their ability to enhance vaccine effectiveness.

Regional Insights

North America emerged as the dominant player in the global Vaccine Adjuvants Market in 2022, holding the largest market share. The region boasts a robust healthcare infrastructure and a well-established pharmaceutical industry, making it a hub for vaccine research, development, and production. North America is home to numerous prominent pharmaceutical companies and research institutions that actively engage in vaccine adjuvant research and innovation. Additionally, stringent regulatory standards and rigorous evaluation processes by agencies like the U.S. Food and Drug Administration (FDA) and Health Canada ensure the safety and efficacy of vaccines and adjuvants. This regulatory framework fosters confidence in adjuvanted vaccines, encouraging their adoption.

Key Market Players

Dynavax Technologies

Croda International Plc

Gsk Plc

Novavax

Spi Pharma (A Subsidiary of Associated British Foods Plc)

Agenus Inc.

Phibro Animal Health Corporation

Aurorium (Formerly Vertellus)

Merck Kgaa

Vaxine Pty Ltd

Report Scope:

In this report, the Global Vaccine Adjuvants Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Vaccine Adjuvants Market, By Product:

• Adjuvant Emulsions
• Pathogen Components
• Saponin-Based Adjuvants
• Particulate Adjuvants
• Other Adjuvants

Global Vaccine Adjuvants Market, By Type:

• Human Vaccine Adjuvants
• Veterinary Vaccine Adjuvants

Global Vaccine Adjuvants Market, By Application:

• Research Applications
• Commercial Applications

Global Vaccine Adjuvants Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Vaccine Adjuvants Market.

Available Customizations:

• Global Vaccine Adjuvants Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Vaccine Adjuvants Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Product (Adjuvant Emulsions, Pathogen Components, Saponin-Based Adjuvants, Particulate Adjuvants, Other Adjuvants)
  • 4.2.2. By Type (Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants)
  • 4.2.3. By Application (Research Applications, Commercial Applications)
  • 4.2.4. By Region
  • 4.2.5. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Product
  • 4.3.2. By Type
  • 4.3.3. By Application
  • 4.3.4. By Region

5. Asia Pacific Vaccine Adjuvants Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product
  • 5.2.2. By Type
  • 5.2.3. By Application
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Vaccine Adjuvants Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Product
      • 5.3.1.2.2. By Type
      • 5.3.1.2.3. By Application
  • 5.3.2. India Vaccine Adjuvants Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Product
      • 5.3.2.2.2. By Type
      • 5.3.2.2.3. By Application
  • 5.3.3. Australia Vaccine Adjuvants Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Product
      • 5.3.3.2.2. By Type
      • 5.3.3.2.3. By Application
  • 5.3.4. Japan Vaccine Adjuvants Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Product
      • 5.3.4.2.2. By Type
      • 5.3.4.2.3. By Application
  • 5.3.5. South Korea Vaccine Adjuvants Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Product
      • 5.3.5.2.2. By Type
      • 5.3.5.2.3. By Application

6. Europe Vaccine Adjuvants Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Type
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Vaccine Adjuvants Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Application
  • 6.3.2. Germany Vaccine Adjuvants Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Application
  • 6.3.3. Spain Vaccine Adjuvants Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Application
  • 6.3.4. Italy Vaccine Adjuvants Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Type
      • 6.3.4.2.3. By Application
  • 6.3.5. United Kingdom Vaccine Adjuvants Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Type
      • 6.3.5.2.3. By Application

7. North America Vaccine Adjuvants Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Type
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Vaccine Adjuvants Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Application
  • 7.3.2. Mexico Vaccine Adjuvants Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Application
  • 7.3.3. Canada Vaccine Adjuvants Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Application

8. South America Vaccine Adjuvants Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Type
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Vaccine Adjuvants Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Application
  • 8.3.2. Argentina Vaccine Adjuvants Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Application
  • 8.3.3. Colombia Vaccine Adjuvants Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Application

9. Middle East and Africa Vaccine Adjuvants Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Type
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Vaccine Adjuvants Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Application
  • 9.3.2. Saudi Arabia Vaccine Adjuvants Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Application
  • 9.3.3. UAE Vaccine Adjuvants Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Application
  • 9.3.4. Egypt Vaccine Adjuvants Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product
      • 9.3.4.2.2. By Type
      • 9.3.4.2.3. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Vaccine Adjuvants Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Dynavax Technologies
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Croda International Plc
• 14.3. Gsk Plc
• 14.4. Novavax
• 14.5. Spi Pharma (A Subsidiary of Associated British Foods Plc)
• 14.6. Agenus Inc.
• 14.7. Phibro Animal Health Corporation
• 14.8. Aurorium (Formerly Vertellus)
• 14.9. Merck Kgaa
• 14.10. Vaxine Pty Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer